Dragonfleye Therapeutics Corp. raised US$37.5 million through two non-brokered private placements of common shares during 2026. Participants included healthcare-dedicated investors and existing shareholders. The ophthalmology company develops platform-based ocular treatments.
Offering terms
The company said both offerings have closed. The shares were issued under prospectus exemptions set out in NI 45-106. They are subject to transfer restrictions and were not registered under U.S. securities laws.
Company context
Dragonfleye is based in Toronto and operates as a near-clinical-stage ophthalmology company. It was co-founded by Rajeev H. Muni, who serves as chief executive officer. The company aims to preserve and restore vision through less invasive treatments.
Platform and pipeline
Its proprietary platform provides nonsurgical, transscleral access to the supraciliary, suprachoroidal, and subretinal spaces. One program targets retinal detachment repair with an injector and a resorbable implant. A second program aims to lower intraocular pressure in open-angle glaucoma and ocular hypertension.
Proceeds will support continued development of its ophthalmic treatments and expansion of its platform technology. The company also plans to grow its partnership pipeline and intellectual property portfolio. Dragonfleye expects to provide progress updates in the months ahead.